Boehringer Ingelheim licenses Immunitas’ preclinical antibody targeting pathogenic immune cells in autoimmune diseases. Up to €407.5M milestones. Strengthens immunology pipeline for unmet needs.
Written By: Sana Khan, BPharm
Reviewed By: Pharmacally Editorial Team
Boehringer Ingelheim has entered a global licensing agreement with Immunitas Therapeutics for a preclinical antibody program targeting chronic inflammatory and autoimmune diseases. The deal strengthens Boehringer Ingelheim’s growing immunology pipeline by adding a novel cell-targeting approach designed to address persistent inflammation.
The investigational antibody selectively targets pathogenic immune cells driving chronic inflammation at affected tissue sites. Unlike conventional therapies that block individual inflammatory pathways or signaling molecules, the strategy is designed to directly target disease-associated immune cell populations with the aim of achieving deeper and more sustained disease control across multiple inflammatory conditions.
Chronic inflammatory and autoimmune diseases affect more than one billion people worldwide, and many patients continue to experience incomplete responses or declining benefit with currently available therapies. The companies said the program was developed to address these unmet needs by targeting the underlying cellular drivers of inflammation rather than isolated inflammatory mediators.
Under the agreement, Boehringer Ingelheim will receive worldwide rights to develop, manufacture, and commercialize the antibody program. Immunitas Therapeutics will receive an undisclosed upfront payment and is eligible for up to €407.5 million in development, regulatory, and commercial milestone payments, in addition to tiered royalties on future sales. Additional financial terms were not disclosed.
Carine Boustany, US Innovation Unit Site Head and Global Head of Immunology and Respiratory Diseases at Boehringer Ingelheim, said the collaboration supports the company’s strategy of expanding its autoimmune and inflammatory disease portfolio with differentiated therapies for patients with limited treatment options.
Amanda Wagner, President and Chief Executive Officer of Immunitas Therapeutics, said the antibody program emerged from the company’s human immunology research and that partnering with Boehringer Ingelheim would help accelerate its advancement into clinical development through the company’s global immunology and drug development capabilities.
The agreement builds on Boehringer Ingelheim’s recent expansion efforts in immunology, including internal research programs and external partnerships focused on autoimmune and inflammatory diseases.
Reference
Boehringer licenses Immunitas ‘novel antibody program | Boehringer Ingelheim
About the Writer
Sana Jamil Khan (LinkedIn) is a B. Pharm graduate with a strong interest in medical writing and scientific communication. Her work focuses on interpreting clinical research, exploring developments in pharmaceutical science, and presenting complex medical information in a clear and accessible manner. She is particularly interested in topics related to human clinical studies, drug safety observations, and emerging therapeutic research.
